

# Molecular Diagnostic Assays and Breath Testing for Transplant Rejection

**Humana**

Medicaid Medical Coverage Policy

Original Effective Date: 01/01/2025

Effective Date: 03/09/2026

Review Date: 11/04/2025

Policy Number: HUM-2158-003

Line of Business: Medicaid

State(s): VA

## Table of Contents

[Description](#)

[Coverage Limitations](#)

[References](#)

[Appendix](#)

[Coverage Determination](#)

[Coding Information](#)

[Change Summary](#)

### Disclaimer

The Medical Coverage Policies are reviewed by the Humana Medicaid Coverage Policy Adoption (MCPA) Forum. Policies in this document may be modified by a member's coverage document. Clinical policy is not intended to preempt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Identification of selected brand names of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test, or procedure over another. Clinical technology is constantly evolving, and we reserve the right to review and update this policy periodically. References to CPT® codes or other sources are for definitional purposes only and do not imply any right to reimbursement or guarantee of claims payment. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any shape or form or by any means, electronic, mechanical, photocopying or otherwise, without permission from Humana.

## Description

A biopsy is considered the gold standard for the diagnosis of organ transplant rejection. Noninvasive methods for the detection and surveillance of transplant rejection have been developed with the goal of reducing the number of biopsies. These tests include, but may not be limited to, the following:

### **Antigen-Specific T-cell Function Assay**

CD154+-T-cytotoxic memory cell testing has been developed to reportedly determine the likelihood of acute cellular rejection by measuring the immune response of recipient lymphocytes to donor or donor-like cells. The tests utilize an index ratio, which purportedly represents cell activity of the T-cytotoxic memory cells toward the donor cells and assesses the risk of rejection. This testing is designed for determining rejection risk in renal transplants (eg, Pleximark Tx) and for pediatric liver and small bowel transplants (eg, Pleximmune).

### **Blood Group Antigen Testing**

Plays a role in recognizing foreign cells in the bloodstream. If a blood type mismatch occurs during a blood transfusion it could lead to an immune response and possible illness. RBC antigen genotyping assays have been proposed as an alternative approach to determining compatibility of donated blood. Blood group

genotyping purportedly overcomes blood grouping limitations by looking directly into the DNA sequence and thereby avoiding any donor cell or antibody interference.

### **Breath Testing**

Breath methylated alkane contour (BMAC) (eg, Heartsbreath) is a test that is purportedly indicated for use as an aid in the diagnosis of [grade 3 heart transplant rejection](#) an individual who have received a heart transplant within the preceding year. It is intended to be used as an adjunct to, and not as a substitute for, an endomyocardial biopsy. The use of the test is limited to an individual who has had an endomyocardial biopsy within the previous month.<sup>33</sup> By breathing into a plastic mouthpiece that is attached to a breath collecting device, the amount of methylated alkanes in the individual's breath is supposedly subtracted from that found in the room. A value is then generated and is compared to the results of a biopsy performed during the previous month to measure the probability of the implanted heart being rejected.

### **Combined Gene Expression Profiling and Donor-Derived Cell-Free (dd-cfDNA) tests**

These tests are designed to reportedly provide a broad assessment of immune quiescence (inactivity) and graft injury by combining a gene expression profiling test and a dd-cfDNA test (eg, OmniGraf).

### **dd-cfDNA**

Biomarker blood tests purportedly determine allograft injury by measuring DNA fragments that are supposedly released into the bloodstream from the injured donor allograft cells. The goal of these tests is to predict active rejection using these measurements. These tests include, but may not be limited to:

- AlloSure
- Viracor TRAC (heart, kidney, liver and lung)
- VitaGraft Kidney

### **Gene Expression Profiling**

Immune response gene expression panel (eg, nCounter Human Organ Transplant Panel) has been developed to assess immune response following organ transplant utilizing a panel of 770 genes across 37 pathways that purportedly evaluates heart, kidney, liver and lung rejection.

Messenger deoxyribonucleic acid (mDNA) and Messenger ribonucleic acid (mRNA) gene expression utilize proprietary microarrays and algorithms based on a reference set of biopsies to provide scores to assess the probability of rejection by reportedly measuring cell-mediated rejection. The tests are purportedly utilized for heart, kidney and lung transplants. Examples of mDNA and mRNA gene expression assays include, but may not be limited to:

- Clarava pretransplant mRNA expression assay
- Molecular Microscope Diagnostic system (eg, MMDx Heart, MMDx Kidney, MMDx Lung)
- TruGraf blood gene expression test
- Tutivia post-transplant mRNA expression assay

Molecular gene expression assay (eg, Kidney Solid Organ Response Test [kSORT]) has been developed for kidney transplant rejection to reportedly detect an individual who is at high risk for acute rejection.

Polymerase chain reaction (PCR) is utilized to measure the relative messenger ribonucleic acid (mRNA) expression levels of 17 genes that have been known to be associated with acute rejection. An individual is classified into high, low or indeterminate risk according to a correlation-based algorithm.<sup>26</sup>

### **Human Leukocyte Antigen Testing**

Human leukocyte antigen (HLA) testing is a process used to determine the compatibility between a donor and a recipient for organ or stem cell transplant. It assesses the HLA antigens present in the blood, which are crucial for the immune system's ability to recognize foreign tissues. The process involves blood tests to analyze the HLA antigens and helps identify suitable tissue donors, improving the chances of a successful transplant.

### **Urine-Based Tests for Allograft Rejection**

Several urine-based tests have been proposed utilizing various biomarkers to aid in the diagnosis of acute rejection in kidney transplant recipients. Purportedly, the tests measure urine mRNA, urine proteins and/or urine proteomics. Some tests measure several biomarkers (eg, QiSant [also known as QSant]) to reportedly determine acute kidney transplant rejection. The biomarkers include, but may not be limited to, cfDNA, methylated cfDNA, clusterin, CXCL10, creatinine and total protein, which are integrated into an algorithm to supposedly determine kidney risk rejection scores.

## **Coverage Determination**

There are no covered indications; refer to Coverage Limitations Section.

**Refer all requests or questions regarding molecular diagnostic assays and breath testing for transplant rejection to the Corporate Transplant Department.**

Phone	Fax	Email
1-866-421-5663	502-508-9300	<a href="mailto:transplant@humana.com">transplant@humana.com</a>

## **Coverage Limitations**

Humana members may **NOT** be eligible under the Plan for any of the following:

- Antigen-specific T-cell function assays (eg, CD154+T-cytotoxic memory cells, Pleximark Tx [0018M], Pleximmune [81560])<sup>22,23</sup>; **OR**
- Breath testing (eg, Heartsbreath [0087U])<sup>6</sup>; **OR**
- Combined Gene Expression Profiling and dd-cfDNA tests (eg, OmniGraf [81479])<sup>18</sup>; **OR**
- dd-cfDNA tests including, but may not be limited to<sup>20</sup>:
  - AlloSure Heart (0540U)

- AlloSure Kidney (0544U)
- Viracor TRAC (heart, kidney, liver, lung [0118U])
- VitaGraft Kidney- Baseline+ First (0508U)
- VitaGraft Kidney- Subsequent (0509U)
- VitaGraft Kidney 2.0 (0544U); **OR**
- HLA testing for transplant rejection (81370-81383)<sup>25,35</sup>; **OR**
- kSORT (81479)<sup>21</sup>; **OR**
- mDNA and mRNA gene expression tests including, but may not be limited to<sup>8,15</sup>:
  - MMDx Heart (0087U)
  - MMDx Kidney (0088U)
  - MMDx Lung (0087U)
  - TruGraf (81479)
  - Clarava (0319U);
  - Tutivia (0320U); **OR**
- nCounter Human Organ Transplant Panel<sup>36</sup> (81479); **OR**
- RBC antigen genotyping assays (eg, PreciseType HEA test [0001U] and ID CORE XT [0084U])<sup>7</sup>; **OR**
- Urine-based tests for allograft rejection<sup>26</sup> (81599) (eg, QiSant [also known as QSant])

A review of the current medical literature shows that the **evidence is insufficient** to determine that these services are standard medical treatments. There is an absence of current, widely-used treatment guidelines or acceptable clinical literature examining benefit and long-term clinical outcomes establishing the value of these services in clinical management.

### Coding Information

Any codes listed on this policy are for informational purposes only. Do not rely on the accuracy and inclusion of specific codes. Inclusion of a code does not guarantee coverage and/or reimbursement for a service or procedure.

CPT® Code(s)	Description	Comments
81370	HLA Class I and II typing, low resolution (eg, antigen equivalents); HLA-A, -B, -C, -DRB1/3/4/5, and -DQB1	
81371	HLA Class I and II typing, low resolution (eg, antigen equivalents); HLA-A, -B, and -DRB1 (eg, verification typing)	

81372	HLA Class I typing, low resolution (eg, antigen equivalents); complete (ie, HLA-A, -B, and -C)	
81373	HLA Class I typing, low resolution (eg, antigen equivalents); one locus (eg, HLA-A, -B, or -C), each	
81374	HLA Class I typing, low resolution (eg, antigen equivalents); one antigen equivalent (eg, B*27), each	
81375	HLA Class II typing, low resolution (eg, antigen equivalents); HLA-DRB1/3/4/5 and -DQB1	
81376	HLA Class II typing, low resolution (eg, antigen equivalents); one locus (eg, HLA-DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each	
81377	HLA Class II typing, low resolution (eg, antigen equivalents); one antigen equivalent, each	
81378	HLA Class I and II typing, high resolution (ie, alleles or allele groups), HLA-A, -B, -C, and -DRB1	
81379	HLA Class I typing, high resolution (ie, alleles or allele groups); complete (ie, HLA-A, -B, and -C)	
81380	HLA Class I typing, high resolution (ie, alleles or allele groups); one locus (eg, HLA-A, -B, or -C), each	
81381	HLA Class I typing, high resolution (ie, alleles or allele groups); one allele or allele group (eg, B*57:01P), each	
81382	HLA Class II typing, high resolution (ie, alleles or allele groups); one locus (eg, HLA-DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each	
81383	HLA Class II typing, high resolution (ie, alleles or allele groups); one allele or allele group (eg, HLA-DQB1*06:02P), each	
81479	Unlisted molecular pathology procedure	
81558	Transplantation medicine (allograft rejection, kidney), mRNA, gene expression profiling by quantitative polymerase chain reaction (qPCR) of 139 genes, utilizing whole blood, algorithm reported as a binary categorization as transplant excellence, which indicates immune quiescence, or not transplant excellence, indicating subclinical rejection	
81560	Transplantation medicine (allograft rejection, pediatric liver and small bowel), measurement of donor and third-party-induced CD154+T-cytotoxic memory cells, utilizing whole peripheral blood, algorithm reported as a rejection risk score	
81599	Unlisted multianalyte assay with algorithmic analysis	

0018M	Transplantation medicine (allograft rejection, renal), measurement of donor and third-party-induced CD154+T-cytotoxic memory cells, utilizing whole peripheral blood, algorithm reported as a rejection risk score	
0001U	Red blood cell antigen typing, DNA, human erythrocyte antigen gene analysis of 35 antigens from 11 blood groups, utilizing whole blood, common RBC alleles reported	
0084U	Red blood cell antigen typing, DNA, genotyping of 10 blood groups with phenotype prediction of 37 red blood cell antigens	
0087U	Cardiology (heart transplant), mRNA gene expression profiling by microarray of 1283 genes, transplant biopsy tissue, allograft rejection and injury algorithm reported as a probability score	
0088U	Transplantation medicine (kidney allograft rejection), microarray gene expression profiling of 1494 genes, utilizing transplant biopsy tissue, algorithm reported as a probability score for rejection	
0118U	Transplantation medicine, quantification of donor-derived cell-free DNA using whole genome next-generation sequencing, plasma, reported as percentage of donor-derived cell-free DNA in the total cell-free DNA	
0319U	Nephrology (renal transplant), RNA expression by select transcriptome sequencing, using pretransplant peripheral blood, algorithm reported as a risk score for early acute rejection	
0320U	Nephrology (renal transplant), RNA expression by select transcriptome sequencing, using posttransplant peripheral blood, algorithm reported as a risk score for acute cellular rejection	
0508U	Transplantation medicine, quantification of donor-derived cell-free DNA using 40 single-nucleotide polymorphisms (SNPs), plasma, and urine, initial evaluation reported as percentage of donor-derived cell-free DNA with risk for active rejection	
0509U	Transplantation medicine, quantification of donor-derived cell-free DNA using up to 12 single-nucleotide polymorphisms (SNPs) previously identified, plasma, reported as percentage of donor-derived cell-free DNA with risk for active rejection	

0540U	Transplantation medicine, quantification of donor-derived cell-free DNA using next-generation sequencing analysis of plasma, reported as percentage of donor-derived cell-free DNA to determine probability of rejection	
0544U	Nephrology (transplant monitoring), 48 variants by digital PCR, using cell-free DNA from plasma, donor-derived cell-free DNA, percentage reported as risk for rejection	
<b>CPT® Category III Code(s)</b>	<b>Description</b>	<b>Comments</b>
No code(s) identified		
<b>HCPCS Code(s)</b>	<b>Description</b>	<b>Comments</b>
No code(s) identified		

## References

1. American College of Cardiology (ACC). 2017 ACC/AHA/HFSA/ISHLT/ACP advanced training statement on advanced heart failure and transplant cardiology (revision of the ACC/AHA/ACP/HFSA/ISHLT 2010 clinical competence statement on management of patients with advanced heart failure and cardiac transplant). <https://acc.org>. Published June 20, 2017.
2. American College of Cardiology (ACC). The end of endomyocardial biopsy? A practical guide for noninvasive heart transplant rejection surveillance. <https://acc.org>. Published March 2023.
3. American Society of Transplant Surgeons (ASTS). ASTS Statement on donor derived cell-free DNA (dd-cfDNA). <https://asts.org>. Published March 6, 2023. Updated October 2024.
4. ClinicalKey. Kransdorf EP, Kobashigawa JA. Heart transplantation. In: Felker GM, Mann DL. *Heart Failure: A Companion to Braunwald's Heart Disease*. 4<sup>th</sup> ed. Elsevier; 2022:1132-1143. <https://clinicalkey.com>.
5. ClinicalKey. Starling, RC. Cardiac transplantation. In: Libby P, Bonow RO, et al. *Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine*. 12<sup>th</sup> ed. Elsevier; 2022:1132-1143. <https://clinicalkey.com>.
6. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD). Heartsbreath test for heart transplant rejection (260.10). <https://cms.gov>. Published December 8, 2008. Updated April 6, 2009.

7. ECRI Institute. Genetic Test Assessment. ID CORE XT genotyping test (Progenika Biopharma S.A., a Grifols Co.) for assessing blood donor-recipient compatibility. <http://home.ecri.org>. Published July 2020.
8. ECRI Institute. Genetic Test Assessment. Molecular diagnostic testing for detecting kidney transplant rejection. <http://home.ecri.org>. Published January 19, 2024.
9. ECRI Institute. Genetic Test Assessment. Molecular diagnostic testing for monitoring heart transplant rejection. <http://home.ecri.org>. Published January 10, 2022.
10. ECRI Institute. Genetic Test Assessment. QSant (NephroSant) for monitoring kidney transplant rejection. <http://home.ecri.org>. Published November 1, 2022.
11. ECRI Institute. Genetic Test Assessment. TruGraf Kidney (Transplant Genomics) for detecting risk for kidney transplant rejection. <http://home.ecri.org>. Published November 4, 2022.
12. ECRI Institute. Genetic Test Assessment. Viracor TRAC kidney dd-cfDNA test (Eurofins Viracor, Inc.) for monitoring kidney transplant rejection. <http://home.ecri.org>. Published February 23, 2022.
13. ECRI Institute. Genetic Test Assessment. Viracor TRAC lung dd-cfDNA test (Eurofins Viracor, Inc.) for monitoring lung transplant rejection. <http://home.ecri.org>. Published May 25, 2022.
14. Gallon L, Chang A, Kattan M, Donovan M. Performance of next-gen sequencing biomarker Tutivia in setting of kidney delayed graft function. <https://vericidx.com>. Published 2024.
15. Hayes, Inc. Molecular Test Assessment. TruGraf Kidney (Eurofins Transplant Genomics). <https://evidence.hayesinc.com>. Published January 27, 2022. Updated June 2, 2025.
16. Hayes, Inc. Precision Medicine Research Brief. kSORT Assay (Immucor). <https://evidence.hayesinc.com>. Published December 5, 2022.
17. Hayes, Inc. Precision Medicine Research Brief. Pleximmune (Plexision). <https://evidence.hayesinc.com>. Published November 4, 2022.
18. Henricksen E, Moayedi Y, Purewal S, et al. Combining donor derived cell free DNA and gene expression profiling for non-invasive surveillance after heart transplantation. *Clin Transplant*. 2023;37(3):e14699.
19. International Society for Heart and Lung Transplantation (ISHLT). The International Society for Heart and Lung Transplantation guidelines for the care of heart transplant recipients. <https://ishlt.org>. Published May 5, 2023.
20. Keller M, Agbor-Enoh S. Donor-derived cell-free DNA for acute rejection monitoring in heart and lung transplantation. *Curr Transplant Rep*. 2021;8(4):351-358.

21. Lee J, Silva J, Bao Y, et al. Performance and advancement of the kidney solid organ response test. *Transplantation*. 2023;107(10):2271-2278.
22. Mehrotra A, Leventhal J, Cravedi P. Monitoring t cell alloreactivity. *Transplant Rev*. 2015;29:53-59.
23. Sindhi R, Ashokkumar C, Higgs B, et al. Profile of the Pleximmune blood test for transplant rejection risk prediction. *Expert Rev Mol Diagn*. 2016;16:387-393.
24. UpToDate, Inc. Heart transplantation in adults: diagnosis of acute allograft rejection. <https://uptodate.com>. Updated May 2025.
25. UpToDate, Inc. Human leukocyte antigens (HLA): a roadmap. <https://uptodate.com>. Updated May 2025.
26. UpToDate, Inc. Investigational methods in the diagnosis of acute kidney allograft rejection. <https://uptodate.com>. Updated May 2025.
27. UpToDate, Inc. Kidney transplantation in adults: clinical features and diagnosis of acute renal allograft rejection. <https://uptodate.com>. Updated May 2025.
28. UpToDate, Inc. Kidney transplantation in adults: treatments of acute T cell-mediated (cellular) rejection. <https://uptodate.com>. Updated May 2025.
29. UpToDate, Inc. Liver transplantation in adults: clinical manifestations and diagnosis of acute T-cell mediated (cellular) rejection of the liver allograft. <https://uptodate.com>. Updated May 2025.
30. UpToDate, Inc. Overview of care of the adult kidney transplant recipient. <https://uptodate.com>. Updated May 2025.
31. UpToDate, Inc. Red blood cell antigens and antibodies. <https://uptodate.com>. Updated June 2025.
32. UpToDate, Inc. Tools for genetics and genomics: gene expression profiling. <https://uptodate.com>. Updated May 2025.
33. US Food & Drug Administration (FDA). Summary of safety and probable benefit: Heartsbreath. <https://fda.gov>. Published October 23, 2002.
34. US Food & Drug Administration (FDA). Summary of safety and probable benefit: Pleximmune. <https://fda.gov>. Published August 26, 2014.
35. Van den Broek D, Meziyerh S, Budda K, et al. The clinical utility of post-transplant monitoring of donor-specific antibodies in stable renal transplant recipients: a consensus report with guideline statements for clinical practice. *Transpl Int*. 2023;36:11321.

36. Varol H, Ernst A, Cristoferi I, et al. Feasibility and potential of transcriptomic analysis using the nanostring ncounter technology to aid the classification of rejection in kidney transplant biopsies. *Transplantation*. 2023;107(4):903-912.
37. VericiDx. Tutivia information sheet. <https://vericidx.com>. Published 2025.

**Appendix**

**Appendix A**

**International Society for Heart and Lung Transplantation (ISHLT) System for Grading Rejection<sup>19</sup>**

Rejection grade	Rejection type	Rejection definition
<b>Grade 0R</b>	No rejection	No interstitial cellular infiltrates
<b>Grade 1R</b>	Mild rejection	Interstitial and/or perivascular cellular infiltrate with less than or equal to one focus of myocyte damage
<b>Grade 2R</b>	Moderate rejection	Greater than or equal to two foci of cellular infiltrate with associated myocyte damage
<b>Grade 3R</b>	Severe rejection	Diffuse cellular infiltrate with multifocal myocyte damage, with or without edema, hemorrhage or vasculitis

**Change Summary**

01/01/2025 New Policy.

05/06/2025 Update, Coverage Change. Updated Coding Information

08/05/2025 Annual Review, No Coverage Change. Updated Coding Information

11/04/2025 Update, Coverage Change. Updated Coding Information